Lorcaserin: Difference between revisions
| Line 50: | Line 50: | ||
===BLOOM-DM=== | ===BLOOM-DM=== | ||
This trial examined the effect of lorcaserin in patients with diabetes mellitus. 16.1% lost 5% or more weight under placebo, whereas 37.5% lost 5% or more under lorecaserin. | This trial examined the effect of lorcaserin in patients with [[diabetes mellitus]]. 16.1% lost 5% or more weight under placebo, whereas 37.5% lost 5% or more under lorecaserin. | ||
==References== | ==References== | ||
Revision as of 20:26, 28 June 2012
|
WikiDoc Resources for Lorcaserin |
|
Articles |
|---|
|
Most recent articles on Lorcaserin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lorcaserin at Clinical Trials.gov Clinical Trials on Lorcaserin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lorcaserin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lorcaserin Discussion groups on Lorcaserin Patient Handouts on Lorcaserin Directions to Hospitals Treating Lorcaserin Risk calculators and risk factors for Lorcaserin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lorcaserin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol".
Mechanism of action
Lorcaserin is a selective 5-HT2C receptor agonist and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets.
5-HT2C receptors are located almost exclusively in the brain, and can also be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus.
The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies.
Side effects
Lorcaserin was approximately as tolerable as placebo in Phase III, with 7% of participants in both the lorcaserin drug and placebo arms dropping out due to side effects.
The drug side effects compared with the placebo are listed in the following table:
| Side effects | Placebo (%) | Drug arm (%) |
|---|---|---|
| Headache (most common) | 11 | 18 |
| Upper respiratory tract infection | 11.9 | 14.8 |
| Nasopharyngitis | 12.0 | 13.4 |
| Nausea | 5.4 | 7.5 |
It was reported by national news-media that lorcaserin was associated with the development of cancer in laboratory rats.[1]
Supportive trial data
BLOOM
BLOOM top line results were released on 30 March 2009. Measurements of efficacy using an intention to treat – last observation carried forward (ITT-LOCF), analysis showed that 47.5% of lorcaserin patients lost at least 5% of their body weight, compared to 20.3% for placebo.
BLOSSOM
BLOSSOM results were released on September 18, 2009. Measurements of efficacy using an intent-to-treat last observation carried forward, or ITT-LOCF, analysis showed that 47.2% of lorcaserin patients lost at least 5% of their body weight, compared to 25.0% for placebo. Lorcaserin patients achieved an average weight loss of 5.9%, or 12.7 pounds, compared to 2.8%, or 6.3 pounds, for placebo.
BLOOM-DM
This trial examined the effect of lorcaserin in patients with diabetes mellitus. 16.1% lost 5% or more weight under placebo, whereas 37.5% lost 5% or more under lorecaserin.
References
- ↑ Larkin, Catherine (15 September 2010). "FDA staff says Arena diet pill linked to cancer". SFGate.